A-Bw4, B-Bw4, B-Bw4-I80, B-Bw4-T80, Bw4, Cancer, Children, Dinutuximab, GM-CSF, HLA-A, HLA-A-Bw4, HLA-B-Bw4, HLA-Bw4, HLA-Bw4 isoforms, HLA-Bw4+, HLA-Bw4-isoforms, I-80, IL-2, KIR, KIR-, KIR-bearing cells, KIR-ligands, KIR3DL1, KIR3DL1+, KIRs, Killer-cell immunoglobulin-like receptors, MHC class I molecules, Patients, Rituximab, T-80, T80, amino acid, anti-CD20 mAb, anti-GD2 mAb, burden follicular lymphoma, cancer, children, isoleucine, isotretinion, isotretinoin, low-tumor, natural killer cells, neuroblastoma, patients, rituximab, threonine